1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

IL-13 antibody

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

11

Inhibitory Antibodies

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99025

    Interleukin Related Inflammation/Immunology
    Lebrikizumab is an IgG4 humanized monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its function. Lebrikizumab can be used for the research of asthma .
    Lebrikizumab
  • HY-P99053

    Interleukin Related Inflammation/Immunology
    Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .
    Tralokinumab
  • HY-P99496

    RPC 4046; ABT 308; CC-93538

    Interleukin Related Inflammation/Immunology
    Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
    Cendakimab
  • HY-P99846

    QAX576

    Interleukin Related Inflammation/Immunology
    Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
    Dectrekumab
  • HY-P99883

    SAR156597

    Interleukin Related Others
    Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
    Romilkimab
  • HY-P99417

    UCB4144; VR 942

    Interleukin Related Inflammation/Immunology
    Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
    Abrezekimab
  • HY-P99238

    Interleukin Related Inflammation/Immunology Cancer
    Rolinsatamab is a potent dual IL-4 and IL-13 inhibitor as a fully humanized bispecific monoclonal antibody. Rolinsatamab chimeric antigen receptor sequence T cell. Rolinsatamab can be used in research of immune disease .
    Rolinsatamab
  • HY-P990093

    CM310

    Interleukin Related Inflammation/Immunology
    Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
    Stapokibart
  • HY-P99870

    ASLAN004; CSL-334

    Interleukin Related Others
    Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .
    Eblasakimab
  • HY-126360

    TNF Receptor Interleukin Related Inflammation/Immunology
    Oxazolone is a haptenizing agent that induces acute or chronic inflammation of the large intestine and is used to construct models of colitis. Oxazolone can cause Th1/Th2-dependent colitis with weight loss and diarrhea. Oxazolone-induced inflammation can be mitigated by neutralizing anti-IL-4 or anti-TNF-α antibodies or decoy IL-13R2-α-FC proteins .
    Oxazolone
  • HY-P99439

    IMA-638

    Interleukin Related Inflammation/Immunology
    Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
    Anrukinzumab
  • HY-P990090

    CBP-201

    Interleukin Related Inflammation/Immunology
    Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
    Rademikibart

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: